Company intelligence / Profile preview

Lumicell

Newton, Massachusetts, United States

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Lumicell’s LumiSystem™, which combines the LUMISIGHT™ optical imaging agent and the Lumicell Direct Visualization System™, received historic dual FDA approval in 2024. Clinical trials demonstrated 84% diagnostic accuracy in detecting residual breast cancer during lumpectomy surgery. The system enables real-time intraoperative visualization of remaining tumor tissue within the surgical cavity—improving complete resection rates and reducing repeat surgeries. In pivotal trials such as INSITE, LumiSystem improved outcomes by identifying additional disease missed by standard methods in about 10% of patients[7][4].

Therapeutic areas: Oncology
Modalities: DeviceOptical imaging agent (pegulicianine)Small molecule (pegulicianine is a small molecule imaging agent)
Industry: Medical Imaging

Drug pipeline

1 asset

pegulicianine

Commercial

Indications: Breast cancer

Partnerships

Academic collaborations with MIT/Koch Institute noted[5].Early adoption at major centers like Stanford University School of Medicine and MD Anderson Cancer Center highlighted as key clinical partners/adopters[4][7].

Beyond the preview

Go deeper on Lumicell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lumicell.

Explore the full profile